Gilder Enterprises

CytoSorbents is a commercial-stage medical device company specializing in blood purification technology for critical care and cardiac surgery. The company's flagship product, CytoSorb, is an extracorporeal cytokine adsorber designed to reduce excessive cytokine levels, often referred to as a "cytokine storm," which can lead to organ failure and death in conditions such as sepsis, trauma, and major surgery. Utilizing a proprietary platform of biocompatible, highly porous polymer beads, the technology actively removes toxic substances from the blood through surface adsorption. CytoSorb is CE Mark approved and has been used in over 200,000 treatments worldwide, primarily in Europe. The company is currently advancing its DrugSorb-ATR system through pivotal Phase 3 trials in the United States to enable the removal of antithrombotic drugs during urgent cardiac surgery.